Wolf's Substack

Wolf's Substack

Share this post

Wolf's Substack
Wolf's Substack
Neuraxis Inc. $NRXS (NYSE)
FINS Reviews

Neuraxis Inc. $NRXS (NYSE)

Q1 2025

Wolf Of Oakville's avatar
Wolf Of Oakville
Jun 26, 2025
∙ Paid
8

Share this post

Wolf's Substack
Wolf's Substack
Neuraxis Inc. $NRXS (NYSE)
Share

Heading south of the border for a rare review of $22M microcap trading on the NYSE per a couple of requests from the Wolf Den discord. The stock has started to get some attention in Canadian small cap circles, so who better to weigh in than your friendly neighbourhood Wolf.

Neuraxis is a growth stage MedTech company who’s main product is a non invasive, non-drug related treatment for children and young adults ages 8-21 who suffer with functional abdominal pain associated with IBS

It’s not surprising that this would start to hit some radars. In late May the company announced FDA approval which expands their leading product to treat additional conditions which the company stated nearly doubles the addressable market.

The stock went from $2.25 to $4 on the news and at one point during the day traded over $6 with over 90M shares traded. At the time the stock had less than 9M tradable shares, therefore turned over more than 10x on the day.

Conveniently, and not coincidentally, the company announced a raise the following day, bringing in $5M on 1.5M shares at $3.25. That news sent the stock back downwards and as of yesterday’s close sits 20% below that share offering.

Enough preamble, let’s get into the numbers.

Wolf of Oakville is a Substack Best Seller producing free and premium paid content for over 3300 subscribers.

Paid Subscriber Benefits:

  • First access to annual picks, upgrades and mid year Seal of Approval picks.

  • Monthly “What’s Wolf Watching” preview of upcoming earnings and potential market moves.

  • FinsDontLie Scholastic Series - exclusive educational posts

  • Access to The Wolf Den discord community (daily insights, charts, chat & Q&A)

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Wolf
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share